Diethylcarbamazine Citrate

CHEMBL937 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
391.4 g/mol
LogP
Phase
4

The citrate salt form of diethylcarbamazine, used in the treatment and prevention of filarial infections, most importantly lymphatic filariasis. This salt form is used in oral tablets and is the standard pharmaceutical preparation of the drug. The citrate salt improves stability and palatability of the medication.

Peso Molecular

391,4200 g/mol

TPSA

159,00 Ų

Mecanismo de Ação

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCN(CC)C(=O)N1CCN(C)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O

InChI

InChI=1S/C10H21N3O.C6H8O7/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-9H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

Molecular Formula

C16H29N3O8

HBD / HBA

4 / 9

Ligações Rotacionáveis

7

Átomos Pesados

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

The citrate salt form of diethylcarbamazine, used in the treatment and prevention of filarial infections, most importantly lymphatic filariasis. This salt form is used in oral tablets and is the standard pharmaceutical preparation of the drug. The citrate salt improves stability and palatability of the medication.

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Yes, Diethylcarbamazine Citrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL937. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 15432. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.